Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473888 | 1.00 | TRPA1 (0.52) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL6478746 | 1.00 | TRPA1 (0.52) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL9421889 | 0.86 | TRPA1 (0.48) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL1715678 | 0.83 | SLC6A2 (0.48) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL28232705 | 0.82 | TRPA1 (0.58) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL10563574 | 0.81 | TRPA1 (0.47) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL10764541 | 0.81 | TRPA1 (0.47) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| Hydrochloric Acid SCHEMBL9320023 | 0.81 | SLC6A2 (0.47) | TRPA1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL7145215 | 0.80 | TAAR1 (0.52) | TAAR1SLC6A2 | |
| SCHEMBL2288262 | 0.79 | MDM2 (0.48) | TRPA1CYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2005012209-A2 | CATALYZED ENANTIOSELECTIVE TRANSFORMATION OF ALKENES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | TRPA1 3653/4885TAAR1 1069/4885SLC6A2 339/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | TRPA1 4867/4885TAAR1 4563/4885SLC6A2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.